OQS
GALT icon

Occudo Quantitative Strategies’s Galectin Therapeutics GALT Stock Holding History

Occudo Quantitative Strategies’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-18,967
Closed -$41K – 944
2021
Q1 		$41K Buy
+18,967
New +$42.5K 0.01% 719

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Occudo Quantitative Strategies's GALT Position: Q2 2021 in Review

Occudo Quantitative Strategies sold out of Galectin Therapeutics (GALT) in Q2 2021, closing a stake of 18,967 shares — an estimated $41K sold.

Occudo Quantitative Strategies first reported a position in GALT in Q1 2021 and held it in 1 quarter. The position peaked at $41K in Q1 2021. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2021.

  • Occudo Quantitative Strategies reported no remaining Galectin Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 18,967 Galectin Therapeutics shares in Q2 2021, an estimated $41K.
  • Occudo Quantitative Strategies first reported a position in Galectin Therapeutics in Q1 2021 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Galectin Therapeutics position peaked at $41K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2021.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.